Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Alzheimer Disease
A common genetic system for functional studies of pitrilysin and related M16A proteases.
Alzheimer Disease
A neglected modulator of insulin-degrading enzyme activity and conformation: The pH.
Alzheimer Disease
Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A? by insulin degrading enzyme (IDE) in Alzheimer's disease.
Alzheimer Disease
Altered expression of insulin-degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E-?4-associated Alzheimer's disease.
Alzheimer Disease
Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Alzheimer Disease
Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.
Alzheimer Disease
Association Between Polymorphisms of the Insulin-Degrading Enzyme Gene and Late-Onset Alzheimer Disease.
Alzheimer Disease
Association of insulin degrading enzyme gene polymorphisms with Alzheimer's disease: a meta-analysis.
Alzheimer Disease
Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme.
Alzheimer Disease
C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study.
Alzheimer Disease
Catalytic Mechanism of Amyloid-? Peptide Degradation by Insulin Degrading Enzyme: Insights from Quantum Mechanics and Molecular Mechanics Style Møller-Plesset Second Order Perturbation Theory Calculation.
Alzheimer Disease
CDK5 Participates in Amyloid-? Production by Regulating PPAR? Phosphorylation in Primary Rat Hippocampal Neurons.
Alzheimer Disease
Characteristics of Insulin-degrading Enzyme in Alzheimer's Disease: A Meta-analysis.
Alzheimer Disease
Characterization of insulin-degrading enzyme-mediated cleavage of A? in distinct aggregation states.
Alzheimer Disease
Chia Seed Does Not Improve Cognitive Impairment in SAMP8 Mice Fed with High Fat Diet.
Alzheimer Disease
Cognitive and Disease-Modifying Effects of 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease.
Alzheimer Disease
Combined risk effects of IDE and NEP gene variants on Alzheimer disease.
Alzheimer Disease
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease.
Alzheimer Disease
Copper(I) and copper(II) inhibit A? peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease.
Alzheimer Disease
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.
Alzheimer Disease
Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.
Alzheimer Disease
Deletion of the fission yeast homologue of human insulinase reveals a TORC1-dependent pathway mediating resistance to proteotoxic stress.
Alzheimer Disease
Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to Abeta and insulin degradation.
Alzheimer Disease
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Alzheimer Disease
Drug Target Engagement Using Coupled Cellular Thermal Shift Assay-Acoustic Reverse-Phase Protein Array.
Alzheimer Disease
Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme.
Alzheimer Disease
Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme.
Alzheimer Disease
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q.
Alzheimer Disease
Functional human insulin-degrading enzyme can be expressed in bacteria.
Alzheimer Disease
Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.
Alzheimer Disease
Ginsenoside Rg1 Decreases A?1-42 Level by Upregulating PPAR? and IDE Expression in the Hippocampus of a Rat Model of Alzheimer's Disease.
Alzheimer Disease
GLP-1 receptor regulates cell growth through regulating IDE expression level in A?1-42-treated PC12 cells.
Alzheimer Disease
Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Alzheimer Disease
Identification of the allosteric regulatory site of insulysin.
Alzheimer Disease
Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Alzheimer Disease
Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE).
Alzheimer Disease
Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.
Alzheimer Disease
Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease.
Alzheimer Disease
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Alzheimer Disease
Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Alzheimer Disease
Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese.
Alzheimer Disease
Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Alzheimer Disease
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Alzheimer Disease
Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.
Alzheimer Disease
Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques.
Alzheimer Disease
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease.
Alzheimer Disease
Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?
Alzheimer Disease
Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Alzheimer Disease
Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population.
Alzheimer Disease
Insulin-degrading enzyme prevents ?-synuclein fibril formation in a nonproteolytical manner.
Alzheimer Disease
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Alzheimer Disease
Insulin-degrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease.
Alzheimer Disease
Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease.
Alzheimer Disease
Insulin-Degrading Enzyme: A Link between Alzheimer's and Type 2 Diabetes Mellitus.
Alzheimer Disease
Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Alzheimer Disease
Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.
Alzheimer Disease
Insulysin: an allosteric enzyme as a target for Alzheimer's disease.
Alzheimer Disease
Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease.
Alzheimer Disease
Links between Alzheimer's disease and diabetes.
Alzheimer Disease
Meta-analysis of the insulin degrading enzyme polymorphisms and susceptibility to Alzheimer's disease.
Alzheimer Disease
Metformin Ameliorates A? Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
Alzheimer Disease
Multiple insulin degrading enzyme variants alter in vitro reporter gene expression.
Alzheimer Disease
Mutation screening of a haplotype block around the insulin degrading enzyme gene and association with Alzheimer's disease.
Alzheimer Disease
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
Alzheimer Disease
No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population.
Alzheimer Disease
Non-covalent interaction of ubiquitin with insulin-degrading enzyme.
Alzheimer Disease
Optimization of Peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.
Alzheimer Disease
Physiological effects of manipulating the level of insulin-degrading enzyme in insulin-producing cells of Drosophila.
Alzheimer Disease
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology.
Alzheimer Disease
Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease.
Alzheimer Disease
Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE.
Alzheimer Disease
PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Alzheimer Disease
Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease.
Alzheimer Disease
Protective effect of Notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer's disease by up-regulating insulin degrading enzyme and inhibiting A? accumulation.
Alzheimer Disease
QM/MM Simulations of Amyloid-? 42 Degradation by IDE in the Presence and Absence of ATP.
Alzheimer Disease
Redox regulation of insulin degradation by insulin-degrading enzyme.
Alzheimer Disease
Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.
Alzheimer Disease
Regulatory feedback cycle of the insulin-degrading enzyme and the amyloid precursor protein intracellular domain: Implications for Alzheimer's disease.
Alzheimer Disease
Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
Alzheimer Disease
Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease.
Alzheimer Disease
Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening.
Alzheimer Disease
Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
Alzheimer Disease
Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway.
Alzheimer Disease
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Alzheimer Disease
Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
Alzheimer Disease
Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease.
Alzheimer Disease
The Association Between Small Vessel Infarcts and the Activities of Amyloid-? Peptide Degrading Proteases in Apolipoprotein E4 AlleleCarriers.
Alzheimer Disease
The association between two single nucleotide polymorphisms within the insulin-degrading enzyme gene and Alzheimer's disease in a Chinese Han population.
Alzheimer Disease
The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.
Alzheimer Disease
The core sequence of PIF competes for insulin/amyloid ? in insulin degrading enzyme: potential treatment for Alzheimer's disease.
Alzheimer Disease
The extracellular matrix enriched with membrane metalloendopeptidase and insulin-degrading enzyme suppresses the deposition of amyloid-beta peptide in Alzheimer's disease cell models.
Alzheimer Disease
The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.
Alzheimer Disease
The metalloendopeptidase gene Pitrm1 is regulated by hedgehog signaling in the developing mouse limb and is expressed in muscle progenitors.
Alzheimer Disease
The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease.
Alzheimer Disease
Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
Alzheimer Disease
Ubiquitin is a novel substrate for human insulin-degrading enzyme.
Alzheimer Disease
[Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease]
Alzheimer Disease
[Effect of tongluo xingnao effervescent tablet on learning and memory of AD rats and expression of insulin-degrading enzyme in hippocampus].
Alzheimer Disease
[Kidney-reinforcing and Governor Vessel-regulating EA Intervention May Improve Learningmemory Possibly by Suppressing Formation of Senile Plaques in Hippocampus in APP/PS 1 Double Transgenic Alzheimer's Disease Mice].
Amyloidosis
Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.
Atherosclerosis
Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice.
Brain Infarction
The Association Between Small Vessel Infarcts and the Activities of Amyloid-? Peptide Degrading Proteases in Apolipoprotein E4 AlleleCarriers.
Brain Ischemia
Pyrrolidine dithiocarbamate attenuates brain A? increase and improves long-term neurological outcome in rats after transient focal brain ischemia.
Carcinoma
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Carcinoma, Hepatocellular
Association of insulin-degrading enzyme with a 70 kDa cytosolic protein in hepatoma cells.
Carcinoma, Hepatocellular
Dexamethasone inhibits insulin binding to insulin-degrading enzyme and cytosolic insulin-binding protein p82.
Carcinoma, Hepatocellular
Identification of insulin-degrading enzyme on the surface of cultured human lymphocytes, rat hepatoma cells, and primary cultures of rat hepatocytes.
Carcinoma, Hepatocellular
In vivo association of [125I]-insulin with a cytosolic insulin-degrading enzyme: detection by covalent cross-linking and immunoprecipitation with a monoclonal antibody.
Carcinoma, Hepatocellular
Inhibition of insulin-degrading enzyme increases translocation of insulin to the nucleus in H35 rat hepatoma cells: evidence of a cytosolic pathway.
Cardiovascular Diseases
Effect of the Interplay Between Genetic and Behavioral Risks on Survival After Age 75.
Cerebellar Ataxia
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.
Cerebral Amyloid Angiopathy
Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.
Cerebral Amyloid Angiopathy
Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.
Chickenpox
Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology?
Chickenpox
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Chickenpox
Insulin degrading enzyme binds to the nonglycosylated precursor of varicella zoster virus gE protein found in the endoplasmic reticulum.
Colonic Neoplasms
Immunohistochemical localization of insulin-degrading enzyme along the rat intestine, in the human colon adenocarcinoma cell line (Caco-2), and in human ileum.
Colonic Neoplasms
Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).
Dementia
Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A? by insulin degrading enzyme (IDE) in Alzheimer's disease.
Dementia
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme.
Dementia
IDE Gene Polymorphism Influences on BPSD in Mild Dementia of Alzheimer's Type.
Dementia
Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia.
Dementia
Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk.
Dementia
Machine Learning and Molecular Dynamics Based Insights into Mode of Actions of Insulin Degrading Enzyme Modulators.
Dementia
Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice.
Dementia
[Effect of tongluo xingnao effervescent tablet on learning and memory of AD rats and expression of insulin-degrading enzyme in hippocampus].
Dementia, Vascular
[Effect of rehabilitation training on insulin-resistance and hippocampus amyloid-beta peptide in rats with vascular dementia].
Diabetes Mellitus
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Diabetes Mellitus
Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
Diabetes Mellitus
Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Diabetes Mellitus
Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Diabetes Mellitus
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Diabetes Mellitus
Insulin-Degrading Enzyme: A Link between Alzheimer's and Type 2 Diabetes Mellitus.
Diabetes Mellitus
Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
Diabetes Mellitus
Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.
Diabetes Mellitus
PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Diabetes Mellitus
Redox regulation of insulin degradation by insulin-degrading enzyme.
Diabetes Mellitus
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Diabetes Mellitus
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
A neglected modulator of insulin-degrading enzyme activity and conformation: The pH.
Diabetes Mellitus, Type 2
Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility.
Diabetes Mellitus, Type 2
Association of polymorphisms in the insulin-degrading enzyme gene with type 2 diabetes in the Korean population.
Diabetes Mellitus, Type 2
C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study.
Diabetes Mellitus, Type 2
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Diabetes Mellitus, Type 2
Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme.
Diabetes Mellitus, Type 2
Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme.
Diabetes Mellitus, Type 2
FADD Phosphorylation Modulates Blood Glucose Levels by Decreasing the Expression of Insulin-Degrading Enzyme.
Diabetes Mellitus, Type 2
GLP-1 receptor regulates cell growth through regulating IDE expression level in A?1-42-treated PC12 cells.
Diabetes Mellitus, Type 2
Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
Diabetes Mellitus, Type 2
High-Density Haplotype Structure and Association Testing of the Insulin-Degrading Enzyme (IDE) Gene With Type 2 Diabetes in 4,206 People.
Diabetes Mellitus, Type 2
IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults.
Diabetes Mellitus, Type 2
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Diabetes Mellitus, Type 2
Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Diabetes Mellitus, Type 2
Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?
Diabetes Mellitus, Type 2
Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Diabetes Mellitus, Type 2
Insulin-degrading enzyme prevents ?-synuclein fibril formation in a nonproteolytical manner.
Diabetes Mellitus, Type 2
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Diabetes Mellitus, Type 2
Insulin-Degrading Enzyme: A Link between Alzheimer's and Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Diabetes Mellitus, Type 2
Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
Diabetes Mellitus, Type 2
Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Pancreatic beta-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and beta-cell functional immaturity.
Diabetes Mellitus, Type 2
Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study.
Diabetes Mellitus, Type 2
Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes.
Diabetes Mellitus, Type 2
PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Diabetes Mellitus, Type 2
Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels.
Diabetes Mellitus, Type 2
Redox regulation of insulin degradation by insulin-degrading enzyme.
Diabetes Mellitus, Type 2
Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice.
Diabetes Mellitus, Type 2
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Diabetes Mellitus, Type 2
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Epilepsy
In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration.
Glioma
Expression of IDE and PITRM1 genes in ERN1 knockdown U87 glioma cells: effect of hypoxia and glucose deprivation.
Glucose Intolerance
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Glucose Intolerance
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice.
Glucose Intolerance
Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice.
Granuloma
Severe insulin resistance associated with subcutaneous amyloid deposition.
Heart Failure
Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.
Herpes Zoster
Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology?
Herpes Zoster
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Herpes Zoster
Insulin degrading enzyme binds to the nonglycosylated precursor of varicella zoster virus gE protein found in the endoplasmic reticulum.
Hyperglycemia
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Hyperglycemia
Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications.
Hyperinsulinism
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Hyperinsulinism
Hyperinsulinemia caused by dexamethasone treatment is associated with reduced insulin clearance and lower hepatic activity of insulin-degrading enzyme.
Hyperinsulinism
Nigella sativa Oil and Chromium Picolinate Ameliorate Fructose-Induced Hyperinsulinemia by Enhancing Insulin Signaling and Suppressing Insulin-Degrading Enzyme in Male Rats.
Hyperinsulinism
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Hyperinsulinism
Reduced Insulin Clearance and Insulin-Degrading Enzyme Activity Contribute to Hyperinsulinemia in African Americans.
Hyperinsulinism
[Dementia and diabetes: Casual or causal relationship?]
Hypertension
Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Hypertension
Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-? (A?) Plaque Load and A?-Synthesizing and A?-Degrading Enzymes in Frontal Cortex.
Hyperthyroidism
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Hypothyroidism
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Infections
The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor.
Infections
The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.
Infections
Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis.
Insulin Resistance
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
Insulin Resistance
Effect of pioglitazone on altered expression of A? metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.
Insulin Resistance
Links between Alzheimer's disease and diabetes.
Insulin Resistance
Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice.
Insulin Resistance
Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.
Insulin Resistance
Reduced insulin clearance and lower insulin-degrading enzyme expression in the liver might contribute to the thrifty phenotype of protein-restricted mice.
Insulin Resistance
Reduced insulin sensitivity and increased ?/? cell mass is associated with reduced hepatic insulin-degrading enzyme activity in pregnant rats.
Insulin Resistance
Relationship between insulin-degrading enzyme activity and insulin sensitivity in cell model of insulin-resistance.
Insulin Resistance
Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus.
Insulin Resistance
[Dementia and diabetes: Casual or causal relationship?]
Insulinoma
An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures.
insulysin deficiency
Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.
insulysin deficiency
Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice.
insulysin deficiency
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.
insulysin deficiency
Role of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration.
Intellectual Disability
Defective PITRM1 mitochondrial peptidase is associated with A? amyloidotic neurodegeneration.
Liver Cirrhosis
Insulin-degrading activity in experimental liver cirrhosis of the rat.
Metabolic Syndrome
Insulin-degrading enzyme higher in subjects with metabolic syndrome.
Metabolic Syndrome
Variants in the insulin-degrading enzyme gene are associated with metabolic syndrome in Chinese elders.
Neoplasms
Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes.
Neoplasms
Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3? Pathway by Hesperidin in Wistar Rats.
Neoplasms
Autophagy-dependent secretion: mechanism, factors secreted, and disease implications.
Neoplasms
Dendrobiumpolysaccharides attenuate cognitive impairment in senescence-accelerated mouse prone 8 mice via modulation of microglial activation.
Neoplasms
Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.
Neoplasms
Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.
Neoplasms
Intracellular insulin in human tumors: examples and implications.
Neoplasms
Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease.
Neoplasms
Lack of association between IDE genetic variability and Down's syndrome.
Neoplasms
No major role for insulin-degrading enzyme in antigen presentation by MHC molecules.
Neoplasms
One for all and all for one: RB defends the cell while IDE, PTEN and IGFBP-7 antagonize insulin and IGFs to protect RB.
Neoplasms
Production of an antigenic peptide by insulin-degrading enzyme.
Neuroblastoma
Novel Platinum(II) compounds modulate insulin-degrading enzyme activity and induce cell death in neuroblastoma cells.
Neuroblastoma
Regulation by retinoic acid of insulin-degrading enzyme and of a related endoprotease in human neuroblastoma cell lines.
Neurodegenerative Diseases
Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.
Neurodegenerative Diseases
Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases.
Neuroinflammatory Diseases
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.
Neuroinflammatory Diseases
Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.
Obesity
Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention.
Obesity
High-Fat Diet Modulates Hepatic Amyloid ? and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease.
Obesity
In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters.
Obesity
Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
Ovarian Neoplasms
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.
Parkinson Disease
6-Hydroxydopamine induces secretion of PARK7/DJ-1 via autophagy-based unconventional secretory pathway.
Parkinsonian Disorders
6-Hydroxydopamine induces secretion of PARK7/DJ-1 via autophagy-based unconventional secretory pathway.
Polycystic Ovary Syndrome
Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome.
Prediabetic State
Relationship Between Cognitive Functions and Insulin-degrading Enzyme in Individuals With Prediabetes.
Retinoblastoma
Intracellular insulin in human tumors: examples and implications.
Retinoblastoma
Retinoblastoma protein co-purifies with proteasomal insulin-degrading enzyme: implications for cell proliferation control.
Spinocerebellar Ataxias
Defective PITRM1 mitochondrial peptidase is associated with A? amyloidotic neurodegeneration.
Spinocerebellar Ataxias
In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration.
Stroke
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme.
Varicella Zoster Virus Infection
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Virus Diseases
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Virus Diseases
Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.